Regulatory T cells and systemic vasculitis.
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
15
12
2022
Statut:
ppublish
Résumé
Emerging data suggest that regulatory T-cells (Treg) alterations play a major role in systemic vasculitis pathophysiology. We performed a systematic review of recent advances in the role of Treg and interleukin (IL)-10 in the pathogenesis and treatment of systemic vasculitis, including giant cell arteritis (GCA), Takayasu arteritis, Behçet's disease, antineutrophil cytoplasm antibodies (ANCA) associated vasculitis (AAV), and cryoglobulinemia associated vasculitis. Emerging data suggest that Treg deficiencies are disease-specific, affecting distinct pathways in distinct vasculitides. Decreased peripheral blood frequencies of Treg are described in all vasculitis when compared to healthy donors. Altered Treg functions are reported in GCA, Takayasu arteritis, AAV, and Behçet's disease with different mechanisms proposed. Treatment with biologics, and sometimes other immunosuppressants, may restore Treg frequencies and/or immune activity with significant differences in active disease or disease in remission in several systemic vasculitis. IL-10 is elevated in GCA, AAV, cryoglobulinemia associated vasculitis. In Behçet's disease, IL-10 is decreased in peripheral blood and elevated in saliva. In Takayasu arteritis, IL-10 levels were essentially elevated in patients' vessel wall. Several new therapeutic approaches targeting Treg and Il-10 (low dose IL-2, CAR Treg…) are developed to treat patients with systemic vasculitis. Treg and IL-10 play a central role in the regulation of inflammation in vasculitis and new targeting approaches are emerging.
Identifiants
pubmed: 36508306
doi: 10.1097/BOR.0000000000000915
pii: 00002281-202301000-00005
doi:
Substances chimiques
Interleukin-10
130068-27-8
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25-30Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1–11.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330–336.
Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531–564.
Ohkura N, Hamaguchi M, Morikawa H, et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 2012; 37:785–799.
Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198:1875–1886.
Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol Baltim Md 19501995; 155:1079–1090.
Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081–2095.
de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915–924.
Kim HJ, Verbinnen B, Tang X, et al. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature 2010; 467:328–332.
Saligrama N, Zhao F, Sikora MJ, et al. Opposing T cell responses in experimental autoimmune encephalomyelitis. Nature 2019; 572:481–487.
Wen Z, Shimojima Y, Shirai T, et al. NADPH oxidase deficiency underlies dysfunction of aged CD8+ Tregs. J Clin Invest 2016; 126:1953–1967.
Terrier B, Geri G, Chaara W, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 2012; 64:2001–2011.
Samson M, Greigert H, Ciudad M, et al. Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. Clin Transl Immunol 2021; 10:e1332.
Miyabe C, Miyabe Y, Strle K, et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 2017; 76:898–905.
Ichiyama K, Yoshida H, Wakabayashi Y, et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem 2008; 283:17003–17008.
Zhou L, Lopes JE, Chong MMW, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453:236–240.
Adriawan IR, Atschekzei F, Dittrich-Breiholz O, et al. Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis. Ann Rheum Dis 2022; 81:124–131.
Jin K, Wen Z, Wu B, et al. NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. J Clin Invest 2021; 131:136042.
Saadoun D, Garrido M, Comarmond C, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol Hoboken NJ 2015; 67:1353–1360.
Jia W, Fu ZL, Wang X, et al. Decreased absolute number of circulating regulatory T cells in patients with Takayasu's arteritis. Front Immunol 2021; 12:768244.
Gao N, Cui W, Zhao LM, et al. Contribution of Th2-like Treg cells to the pathogenesis of Takayasu's arteritis. Clin Exp Rheumatol 2020; 38:48–54.
Morgan MD, Day CJ, Piper KP, et al. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010; 130:64–73.
Free ME, Bunch DO, McGregor JA, et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum 2013; 65:1922–1933.
Wang Y, Zhang S, Zhang N, et al. Reduced activated regulatory T cells and imbalance of Th17/activated Treg cells marks renal involvement in ANCA-associated vasculitis. Mol Immunol 2020; 118:19–29.
Dekkema GJ, Bijma T, Jellema PG, et al. Increased miR-142-3p expression might explain reduced regulatory T cell function in granulomatosis with polyangiitis. Front Immunol 2019; 10:2170.
Szczeklik W, Jakieła B, Wawrzycka-Adamczyk K, et al. Skewing toward Treg and Th2 responses is a characteristic feature of sustained remission in ANCA-positive granulomatosis with polyangiitis. Eur J Immunol 2017; 47:724–733.
Gan PY, Dick J, O'Sullivan KM, et al. Anti-CD20 mAb-induced B cell apoptosis generates T cell regulation of experimental myeloperoxidase ANCA-associated vasculitis. J Am Soc Nephrol JASN 2021; 32:1071–1083.
Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004; 103:3428–3430.
Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365:2067–2077.
Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 2017; 153:49–52.
Saadoun D, Rosenzwajg M, Landau D, et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111:5334–5341.
Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011; 128:655–664.
Gündüz E, Teke HU, Bilge NSY, et al. Regulatory T cells in Behçet's disease: is there a correlation with disease activity? Does regulatory T cell type matter? Rheumatol Int 2013; 33:3049–3054.
Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480–483.
Bucher C, Koch L, Vogtenhuber C, et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 2009; 114:5375–5384.
Filleron A, Tran TA, Hubert A, et al. Regulatory T cell/Th17 balance in the pathogenesis of paediatric Behçet disease. Rheumatol Oxf Engl 2021; 61:422–429.
Ahmadi M, Yousefi M, Abbaspour-Aghdam S, et al. Disturbed Th17/Treg balance, cytokines, and miRNAs in peripheral blood of patients with Behcet's disease. J Cell Physiol 2019; 234:3985–3994.
Ueda S, Akahoshi M, Takeda A, et al. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease. Eur J Rheumatol 2018; 5:9–15.
Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737–742.
Chaudhry A, Samstein RM, Treuting P, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011; 34:566–578.
Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci 1992; 89:1890–1893.
Lelievre E, Sarrouilhe D, Morel F, et al. Preincubation of human resting T cell clones with interleukin 10 strongly enhances their ability to produce cytokines after stimulation. Cytokine 1998; 10:831–840.
Groux H, Bigler M, Vries JEde, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T Cells. J Immunol 1998; 160:3188–3193.
Lauw FN, Pajkrt D, Hack CE, et al. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol Baltim Md 19502000; 165:2783–2789.
Desbois AC, Cacoub P, Leroyer AS, et al. Immunomodulatory role of interleukin-33 in large vessel vasculitis. Sci Rep 2020; 10:6405.
Fukui S, Kuwahara-Takaki A, Ono N, et al. Serum levels of fibroblast growth factor-2 distinguish Takayasu arteritis from giant cell arteritis independent of age at diagnosis. Sci Rep 2019; 9:688.
Hadjimi Z, Belguendouz H, Benchabane S, et al. Increased salivary cytokines and nitric oxide levels in Behçet's disease: interleukin-32, a novel player in disease prognosis. Endocr Metab Immune Disord Drug Targets 2022; doi: 10.2174/1871530322666220512120948. [Online ahead of print].
doi: 10.2174/1871530322666220512120948.
Novak T, Hamedi M, Bergmeier LA, et al. Saliva and serum cytokine profiles during oral ulceration in Behçet's disease. Front Immunol 2021; 12:724900.
Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010; 42:698–702.
Touzot M, Cacoub P, Bodaghi B, et al. IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. Autoimmun Rev 2015; 14:370–375.
Hoffmann JC, Patschan D, Dihazi H, et al. Cytokine profiling in anti neutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional cohort study. Rheumatol Int 2019; 39:1907–1917.
Jung JH, Song GG, Lee YH. Meta-analysis of associations between interleukin-10 polymorphisms and susceptibility to vasculitis. Immunol Invest 2015; 44:553–565.
Saadoun D, Boyer O, Trébeden-Nègre H, et al. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 2004; 41:1031–1037.
Cielecka-Kuszyk J, Siennicka J, Jabłońska J, et al. Is interleukin-8 an additional to histopathological changes diagnostic marker in HCV-infected patients with cryoglobulinemia? Hepatol Int 2011; 5:934–940.
Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol Baltim Md 19501995; 154:5492–5499.
Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis 2019; 78:209–217.
Wu R, Mu Y, Zhao X, et al. Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis. Autoimmun Rev 2022; 21:103156.
Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol Orlando Fla 2014; 153:23–30.
Duarte JH, Zelenay S, Bergman ML, et al. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 2009; 39:948–955.
MacDonald KG, Hoeppli RE, Huang Q, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest 2016; 126:1413–1424.
Tenspolde M, Zimmermann K, Weber LC, et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun 2019; 103:102289.
Whittington KB, Prislovsky A, Beaty J, et al. CD8+ T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4+ T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis. J Immunol Baltim Md 19502022; 208:16–26.
Tang XJ, Sun XY, Huang KM, et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget 2015; 6:44179–44190.